Skip to main content
VENUS: Ustekinumab appears superior to vedolizumab for refractory Crohn’s disease
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
VENUS: Ustekinumab appears superior to vedolizumab for refractory Crohn’s disease
User login
Username
Password
Reset your password
concept
Lead
score
Crohn Disease
1
1
Specialty
Lead
score
Gastroenterology
1
1